within Pharmacolibrary.Drugs.ATC.A;

model A03CB04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.13,
    Cl             = 120 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 5 / 1000000,
    adminCount     = 1,
    Vd             = 0.0025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.002,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Combination drug containing homatropine methylbromide, a muscarinic antagonist used for gastrointestinal disorders, and various psycholeptics such as barbiturates. Historically used to treat peptic ulcers and GI spasms with additional sedative/anti-anxiety effects. Not widely used or approved in most modern formularies today.</p><h4>Pharmacokinetics</h4><p>No published human pharmacokinetic studies available for the combination of homatropine methylbromide and psycholeptics. Monographs for oral homatropine methylbromide were used for estimation in healthy adults.</p><h4>References</h4><ol></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A03CB04;
